More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.46B
EPS
3.63
P/E ratio
29.7
Price to sales
2.09
Dividend yield
--
Beta
0.52117
Previous close
$75
Today's open
$75.23
Day's range
$74.67 - $76.58
52 week range
$47.32 - $87.32
show more
CEO
Christopher A. Simon
Employees
3023
Headquarters
Boston, MA
Exchange
New York Stock Exchange
Shares outstanding
45445983
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.
PRNewsWire • Jul 8, 2026

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
Zacks Investment Research • Jul 3, 2026

Pharvaris Announces Annual General Meeting of Shareholders
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
GlobeNewsWire • Jun 11, 2026

Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • Jun 8, 2026

Haemonetics Updates Financial Reporting Segments
BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two.
PRNewsWire • Jun 5, 2026

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
PRNewsWire • Jun 2, 2026

Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Zacks Investment Research • May 22, 2026

Is the Options Market Predicting a Spike in Haemonetics Stock?
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Zacks Investment Research • May 13, 2026

Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • May 12, 2026

HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Zacks Investment Research • May 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Haemonetics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.